|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/15/22 Cyclo Therapeutics, Inc. 10-Q 6/30/22 44:3.2M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 580K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 19K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 19K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 14K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 14K
11: R1 Document And Entity Information HTML 71K
12: R2 Consolidated Balance Sheets (Current Period HTML 97K
Unaudited)
13: R3 Consolidated Balance Sheets (Current Period HTML 30K
Unaudited) (Parentheticals)
14: R4 Consolidated Statements of Operations (Unaudited) HTML 88K
15: R5 Consolidated Statements of Stockholders' Equity HTML 70K
(Unaudited)
16: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 87K
17: R7 Note 1 - Summary of Significant Accounting HTML 56K
Policies
18: R8 Note 2 - Revenues HTML 35K
19: R9 Note 3 - Major Customers and Suppliers HTML 18K
20: R10 Note 4 - Mortgage Note Receivable HTML 17K
21: R11 Note 5 - Note Payable HTML 21K
22: R12 Note 6 - Equity Transactions HTML 27K
23: R13 Note 7 - Income Taxes HTML 19K
24: R14 Note 8 - Equity Incentive Plan HTML 22K
25: R15 Note 9 - Net Loss Per Share HTML 37K
26: R16 Note 10 - Subsequent Events HTML 17K
27: R17 Significant Accounting Policies (Policies) HTML 99K
28: R18 Note 2 - Revenues (Tables) HTML 29K
29: R19 Note 9 - Net Loss Per Share (Tables) HTML 37K
30: R20 Note 1 - Summary of Significant Accounting HTML 60K
Policies (Details Textual)
31: R21 Note 2 - Revenues (Details Textual) HTML 23K
32: R22 Note 2 - Revenues - Revenues by Product (Details) HTML 27K
33: R23 Note 3 - Major Customers and Suppliers (Details HTML 28K
Textual)
34: R24 Note 4 - Mortgage Note Receivable (Details HTML 21K
Textual)
35: R25 Note 5 - Note Payable (Details Textual) HTML 15K
36: R26 Note 6 - Equity Transactions (Details Textual) HTML 94K
37: R27 Note 8 - Equity Incentive Plan (Details Textual) HTML 62K
38: R28 Note 9 - Net Loss Per Share - Earnings Per Share HTML 34K
(Details)
39: R29 Note 9 - Net Loss Per Share - Antidilutive HTML 19K
Securities Weighted Average Shares Outstanding
(Details)
42: XML IDEA XML File -- Filing Summary XML 74K
40: XML XBRL Instance -- ctdh20220630_10q_htm XML 703K
41: EXCEL IDEA Workbook of Financial Reports XLSX 69K
7: EX-101.CAL XBRL Calculations -- ctdh-20220630_cal XML 80K
8: EX-101.DEF XBRL Definitions -- ctdh-20220630_def XML 664K
9: EX-101.LAB XBRL Labels -- ctdh-20220630_lab XML 542K
10: EX-101.PRE XBRL Presentations -- ctdh-20220630_pre XML 672K
6: EX-101.SCH XBRL Schema -- ctdh-20220630 XSD 94K
43: JSON XBRL Instance as JSON Data -- MetaLinks 221± 347K
44: ZIP XBRL Zipped Folder -- 0001437749-22-020532-xbrl Zip 140K
EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934
I, Joshua M. Fine, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q of Cyclo Therapeutics, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d. |
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
|
5. |
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
|
Date: August 15, 2022 |
By: |
/s/ Joshua M. Fine |
|
Chief Financial Officer |
||
|
(principal financial and accounting officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/15/22 | None on these Dates | ||
| For Period end: | 6/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/10/23 Cyclo Therapeutics, Inc. S-1/A 2:351K RDG Filings/FA 1/27/23 Cyclo Therapeutics, Inc. S-1 4:320K RDG Filings/FA 1/03/23 Cyclo Therapeutics, Inc. 424B5 1:345K RDG Filings/FA 11/21/22 Cyclo Therapeutics, Inc. S-1/A 6:905K RDG Filings/FA 10/31/22 Cyclo Therapeutics, Inc. S-1 3:528K RDG Filings/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/25/21 Cyclo Therapeutics, Inc. 8-K:5,9 6/24/21 3:634K RDG Filings/FA 11/10/20 Cyclo Therapeutics, Inc. 8-K:3,5,9 11/06/20 4:1.2M RDG Filings/FA |